Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
24
KURA Quote, Financials, Valuation and Earnings
Last price:
$8.93
Seasonality move
:
7.83%
Day range:
$8.88 - $9.17
52-week range:
$8.85 - $24.17
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.65x
Volume:
3.2M
Avg. volume:
2.5M
1-year change:
-27.04%
Market cap:
$700.7M
Revenue:
--
EPS (TTM):
-$2.36
Analysts' Opinion
-
Consensus RatingKura Oncology has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Kura Oncology has an estimated upside of 217.11% from its current price of $9.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $9.01.
Fair Value
-
According to the consensus of 0 analysts, Kura Oncology has 217.11% upside to fair value with a price target of -- per share.
KURA vs. S&P 500
-
Over the past 5 trading days, Kura Oncology has underperformed the S&P 500 by -4.54% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kura Oncology does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kura Oncology has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Kura Oncology reported revenues of --.
Earnings Growth
-
Kura Oncology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kura Oncology reported earnings per share of -$0.63.
Enterprise value:
254.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.51x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$137.7M | -$154.2M | -$217.5M | -$42.5M | -$59.9M | |
| EBITDA | -$134.8M | -$140.7M | -$195.1M | -$38M | -$53.8M | |
| Diluted EPS | -$2.03 | -$2.02 | -$2.36 | -$0.50 | -$0.63 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $328.9M | $548.9M | $436.4M | $459.9M | $463.2M | |
| Total Assets | $339.6M | $561.1M | $448M | $473.8M | $478.8M | |
| Current Liabilities | $21.7M | $21.9M | $24.7M | $27.5M | $40.4M | |
| Total Liabilities | $33.1M | $27.4M | $28.4M | $43.8M | $55.1M | |
| Total Equity | $306.5M | $533.8M | $419.6M | $429.9M | $423.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$106.9M | -$117M | -$169.1M | -$29M | -$43.4M | |
| Cash From Investing | $154M | -$74M | $35.6M | $8.6M | $45.5M | |
| Cash From Financing | $4.6M | $128.8M | $154.3M | $84K | $2.2M | |
| Free Cash Flow | -$107.6M | -$117.2M | -$169.2M | -$29M | -$43.4M | |
KURA
Sector
Market Cap
$700.7M
$43.9M
Price % of 52-Week High
37.28%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-27.05%
-29.11%
Beta (5-Year)
0.746
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$9.54
200-day SMA
Sell
Level
$18.96
Bollinger Bands (100)
Sell
Level
13.36 - 20.72
Chaikin Money Flow
Sell
Level
-33.8M
20-day SMA
Sell
Level
$10.33
Relative Strength Index (RSI14)
Sell
Level
22.05
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-93.7008
50-day SMA
Sell
Level
$14.44
MACD (12, 26)
Sell
Level
-1.55
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-1.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Stock Forecast FAQ
In the current month, KURA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KURA average analyst price target in the past 3 months is --.
-
Where Will Kura Oncology Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kura Oncology share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Kura Oncology?
Analysts are divided on their view about Kura Oncology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kura Oncology is a Sell and believe this share price will drop from its current level to --.
-
What Is Kura Oncology's Price Target?
The price target for Kura Oncology over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KURA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kura Oncology is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KURA?
You can purchase shares of Kura Oncology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kura Oncology shares.
-
What Is The Kura Oncology Share Price Today?
Kura Oncology was last trading at $8.93 per share. This represents the most recent stock quote for Kura Oncology. Yesterday, Kura Oncology closed at $9.01 per share.
-
How To Buy Kura Oncology Stock Online?
In order to purchase Kura Oncology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
